药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Zuclopenthixol
Bermekimab
The risk or severity of adverse effects can be increased when Bermekimab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Rozanolixizumab
The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Refanezumab
The risk or severity of adverse effects can be increased when Refanezumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Bevacizumab zirconium Zr-89
The risk or severity of adverse effects can be increased when Bevacizumab zirconium Zr-89 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Emactuzumab
The risk or severity of adverse effects can be increased when Emactuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Parsatuzumab
The risk or severity of adverse effects can be increased when Parsatuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Vobarilizumab
The risk or severity of adverse effects can be increased when Vobarilizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Lintuzumab
The risk or severity of adverse effects can be increased when Lintuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Xentuzumab
The risk or severity of adverse effects can be increased when Xentuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Brolucizumab
The risk or severity of adverse effects can be increased when Brolucizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Codrituzumab
The risk or severity of adverse effects can be increased when Codrituzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Icrucumab
The risk or severity of adverse effects can be increased when Icrucumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Isatuximab
The risk or severity of adverse effects can be increased when Isatuximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Anetumab ravtansine is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Gancotamab
The risk or severity of adverse effects can be increased when Gancotamab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Setrusumab
The risk or severity of adverse effects can be increased when Setrusumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Camrelizumab
The risk or severity of adverse effects can be increased when Camrelizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Risankizumab
The risk or severity of adverse effects can be increased when Risankizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Emapalumab
The risk or severity of adverse effects can be increased when Emapalumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Cemiplimab
The risk or severity of adverse effects can be increased when Cemiplimab is combined with Trastuzumab deruxtecan.